Ceredex Value Advisors LLC Takes Position in Thermo Fisher Scientific Inc. $TMO

Posted by George Bondi on Aug 21st, 2026

Ceredex Value Advisors LLC bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 51,619 shares of the medical research company’s stock, valued at approximately $25,880,000.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC boosted its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after acquiring an additional 988 shares in the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after purchasing an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $170,000. Raymond James Financial Inc. raised its holdings in Thermo Fisher Scientific by 7.4% during the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock worth $315,781,000 after buying an additional 53,542 shares during the period. Finally, California State Teachers Retirement System boosted its holdings in shares of Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock worth $244,099,000 after buying an additional 2,262 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Thermo Fisher Scientific Stock Up 2.4%

Shares of NYSE TMO opened at $628.24 on Friday. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The stock has a market cap of $232.29 billion, a PE ratio of 33.79, a PEG ratio of 2.50 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52-week low of $435.27 and a 52-week high of $643.99. The business has a fifty day moving average of $539.33 and a two-hundred day moving average of $508.86.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. During the same period last year, the company posted $4.28 earnings per share. The firm’s quarterly revenue was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is 10.11%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Morgan Stanley boosted their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, August 1st. Sanford C. Bernstein initiated coverage on Thermo Fisher Scientific in a report on Friday, June 26th. They issued a “market perform” rating and a $520.00 target price for the company. Piper Sandler lifted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. Based on data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus target price of $619.41.

Get Our Latest Research Report on TMO

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the transaction, the chief operating officer directly owned 24,651 shares in the company, valued at $13,927,815. This represents a 1.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,493 shares of company stock worth $37,657,681 over the last three months. Company insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.